BACKGROUND: Neurotoxicity is common after modern chemotherapy, and can be assessed both objectively and subjectively based on symptoms reported by patients. The aim of this study was to explore the psychometric properties of a brief self-report scale for chemotherapy induced long-term neurotoxicity (the SCIN). METHODS: As part of a questionnaire survey 684 testicular cancer survivors (TCSs) filled in the SCIN, which assesses peripheral sensory neuropathy (paresthesias), Raynaud's phenomenon, and ototoxicity. Factor structure and internal consistency reliability of the SCIN were tested by the split-half method. In 538 TCSs, audiogram data were compared to the patients SCIN ratings of hearing. RESULTS: The internal consistency of the SCIN showed a Cronbach's alpha of 0.72. The three-factor structure of the SCIN was confirmed with 77% explained variance. All the SCIN items discriminated significantly between the TCSs who had been treated with cisplatin-based chemotherapy vs. those who did not receive such treatment. The individual cumulative cisplatin dose correlated significantly with all the SCIN items. The Pearson product-moment correlation coefficient was 0.54 between hearing reduction at 4000 Hertz measured by audiogram and the SCIN self-report of reduced hearing. CONCLUSION: The SCIN shows good psychometric properties, and is recommended as a brief screening instrument for chemotheraphy-indeed neurotoxicity.
BACKGROUND: Neurotoxicity is common after modern chemotherapy, and can be assessed both objectively and subjectively based on symptoms reported by patients. The aim of this study was to explore the psychometric properties of a brief self-report scale for chemotherapy induced long-term neurotoxicity (the SCIN). METHODS: As part of a questionnaire survey 684 testicular cancer survivors (TCSs) filled in the SCIN, which assesses peripheral sensory neuropathy (paresthesias), Raynaud's phenomenon, and ototoxicity. Factor structure and internal consistency reliability of the SCIN were tested by the split-half method. In 538 TCSs, audiogram data were compared to the patients SCIN ratings of hearing. RESULTS: The internal consistency of the SCIN showed a Cronbach's alpha of 0.72. The three-factor structure of the SCIN was confirmed with 77% explained variance. All the SCIN items discriminated significantly between the TCSs who had been treated with cisplatin-based chemotherapy vs. those who did not receive such treatment. The individual cumulative cisplatin dose correlated significantly with all the SCIN items. The Pearson product-moment correlation coefficient was 0.54 between hearing reduction at 4000 Hertz measured by audiogram and the SCIN self-report of reduced hearing. CONCLUSION: The SCIN shows good psychometric properties, and is recommended as a brief screening instrument for chemotheraphy-indeed neurotoxicity.
Authors: E A Calhoun; E E Welshman; C-H Chang; J R Lurain; D A Fishman; T L Hunt; D Cella Journal: Int J Gynecol Cancer Date: 2003 Nov-Dec Impact factor: 3.437
Authors: H R Maricq; P H Carpentier; M C Weinrich; J E Keil; A Franco; P Drouet; O C Ponçot; M V Maines Journal: J Rheumatol Date: 1993-01 Impact factor: 4.666
Authors: Sophie D Fosså; Ronald de Wit; J Trevor Roberts; Peter M Wilkinson; Pieter H M de Mulder; Graham M Mead; Pat Cook; Linda de Prijck; Sally Stenning; Neil K Aaronson; Andrew Bottomley; Laurence Collette Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: David H Moore; James Donnelly; William P McGuire; Lois Almadrones; David F Cella; Thomas J Herzog; Steven E Waggoner Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: Christian Falk Dahl; Hege Sagstuen Haugnes; Roy Bremnes; Olav Dahl; Sophie D Fosså; Olbjørn Klepp; Erik Wist; Alv A Dahl Journal: J Cancer Surviv Date: 2010-06-24 Impact factor: 4.442
Authors: Robert D Frisina; Heather E Wheeler; Sophie D Fossa; Sarah L Kerns; Chunkit Fung; Howard D Sesso; Patrick O Monahan; Darren R Feldman; Robert Hamilton; David J Vaughn; Clair J Beard; Amy Budnick; Eileen M Johnson; Shirin Ardeshir-Rouhani-Fard; Lawrence H Einhorn; Steven E Lipshultz; M Eileen Dolan; Lois B Travis Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544
Authors: Mia Hashibe; Sarah Abdelaziz; Mohammed Al-Temimi; Alison Fraser; Kenneth M Boucher; Ken Smith; Yuan-Chin Amy Lee; Kerry Rowe; Braden Rowley; Micky Daurelle; Avery E Holton; James VanDerslice; Lorenzo Richiardi; Jay Bishoff; Will Lowrance; Antoinette Stroup Journal: J Cancer Surviv Date: 2016-05-11 Impact factor: 4.442
Authors: Alv A Dahl; Marie Østby-Deglum; Jan Oldenburg; Roy Bremnes; Olav Dahl; Olbjørn Klepp; Erik Wist; Sophie D Fosså Journal: J Cancer Surviv Date: 2016-02-26 Impact factor: 4.442
Authors: Matthew R Trendowski; Omar El-Charif; Mark J Ratain; Patrick Monahan; Zepeng Mu; Heather E Wheeler; Paul C Dinh; Darren R Feldman; Shirin Ardeshir-Rouhani-Fard; Robert J Hamilton; David J Vaughn; Chunkit Fung; Christian Kollmannsberger; Taisei Mushiroda; Michiaki Kubo; Robyn Hannigan; Frederick Strathmann; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis; M Eileen Dolan Journal: Clin Cancer Res Date: 2019-07-11 Impact factor: 12.531
Authors: Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith Journal: Semin Oncol Nurs Date: 2019-04-30 Impact factor: 2.315
Authors: Tito R Mendoza; Xin Shelley Wang; Loretta A Williams; Qiuling Shi; Elisabeth G Vichaya; Patrick M Dougherty; Sheeba K Thomas; Emre Yucel; Christel C Bastida; Jeanie F Woodruff; Charles S Cleeland Journal: J Pain Date: 2015-07-22 Impact factor: 5.820
Authors: Marianne Brydøy; Jan Oldenburg; Olbjørn Klepp; Roy M Bremnes; Erik A Wist; Tore Wentzel-Larsen; Erik R Hauge; Olav Dahl; Sophie D Fosså Journal: J Natl Cancer Inst Date: 2009-12-16 Impact factor: 13.506